title: Progress toward in vivo use of siRNAs-II.
abstract: RNA interference (RNAi) has been extensively employed for in vivo research since its use was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it is now routinely possible to obtain reagents that suppress expression of any gene desired. At the same time, increased understanding of the molecular basis of unwanted side effects has led to the development of chemical modification strategies that mitigate these concerns. Delivery remains the single greatest hurdle to widespread adoption of in vivo RNAi methods. However, exciting advances have been made and new delivery systems under development may help to overcome these barriers. This review discusses advances in RNAi biochemistry and biology that impact in vivo use and provides an overview of select publications that demonstrate interesting applications of these principles. Emphasis is placed on work with synthetic, small interfering RNAs (siRNAs) published since the first installment of this review which appeared in 2006.
authors.affiliation: Integrated DNA Technologies, Inc., Coralville, Iowa 52241, USA.
authors.forename: Garrett R
authors.initials: GR
authors.lastname: Rettig
authors.forename: Mark A
authors.initials: MA
authors.lastname: Behlke
mesh_terms: D000818:Animals; D016503:Drug Delivery Systems / Q000639:trends; D006801:Humans; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D034741:RNA, Small Interfering